Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes

Brain, Behavior, and Immunity

Volumn 16, Issue 5, 2002, Pages 544-556

  Anisman, Hymie ^a   Kokkinidis, Larry ^b   Merali, Zul ^c  

^a CARLETON UNIVERSITY   (Canada)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anxiety; Depression; Dopamine; Interleukin 1; Interleukin 2; Lipopolysaccharide; Norepinephrine; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LIPOPOLYSACCHARIDE; MONOAMINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; VANOXERINE; NORADRENALIN;

ANHEDONIA; COGNITION; CONFERENCE PAPER; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; CYTOKINE PRODUCTION; DEPRESSION; DOPAMINE RELEASE; DRUG EFFECT; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMUNE SYSTEM; LEARNING; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; STRESS; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; COGNITIVE DEFECT; HUMAN; IMMUNOLOGY; MEMORY DISORDER; MOOD DISORDER; REVIEW;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; COGNITION DISORDERS; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DOPAMINE; ENDOTOXINS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; LEARNING; MEMORY DISORDERS; MOOD DISORDERS; NOREPINEPHRINE; SEROTONIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036428988     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(02)00011-9     Document Type: Conference Paper

References (101)

1. 3H]dopamine in rat cultured mesencephalic cells. J. Neurochem., 61, 1284-1290.
2. Ando, T., & Dunn, A. J. (1999). Mouse tumor necrosis factor-alpha increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation, 6, 319-329.
3. Anisman, H., & Merali, Z. (1999). Anhedonic and anxiogenic effects of cytokine exposure. Adv. Exp. Med. Biol., 461, 199-233.
4. Anisman, H., Kokkinidis, L., & Merali, Z. (1996). Influence of interleukin-2 on responding for electrical brain stimulation from the hypothalamus. Brain Res., 73, 1-11.
5. Anisman, H., Kokkinidis, L., Borowski, T., & Merali, Z. (1998). Differential effects of IL-1, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res., 779, 177-187.
6. Anisman, H., Hayley, S., Staines, W., & Merali, Z. (2001). Cytokines, stress, and neurochemical change: Immediate and proactive effects. In C. A. Shaw & J. C. McEachern (Eds.), Towards a Theory of Neuroplas-ticity (pp. 301-320). Philadelphia: Psychology Press.
7. Anisman, H., Zalcman, S., Shanks, N., & Zacharko, R. M. (1991). Multisystem regulation of performance deficits induced by stressors: An animal model of depression. In A. Boulton, G. Baker, & M. Martin-Iverson (Eds.), Neuromethods, vol. 19: Animal Models of Psychiatry, II (pp. 1-59). New Jersey: Humana Press.
8. Araujo, B. M., & Lapchak, P. A. (1994). Induction of immune system mediators in the hippocampal formation of Alzheimer's and Parkinson's disease: Slecetive effects on specific interleukins and interleukin receptors. Neuroscience, 61, 745-754.
9. Araujo, B. M., Lapchak, P. A., Collier, B., & Quirion, R. (1989). Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: Interaction with the cholinergic system. Brain Res., 498, 257-266.
10. Banks, W. A. (2001). Cytokines, CVSs, and the blood-brain-barrier. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 483-498). New York: Academic Press.
11. Banks, W. A. (1999). Physiology and pathology of the blood-brain barrier: Implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol., 5, 538-555.
12. Banks, W. A., & Kastin, A. J. (1992). The interleukins-1α, -1β and -2 do not acutely disrupt the murine blood-brain barrier. Int. J. Immunopharmacol., 14, 629-636.
13. Bartholomew, S. A., & Hoffman, S. A. (1993). Effects of peripheral cytokine injections on multiple unit activity in the anterior hypothalamic area of the mouse. Brain Behav. Immun., 7, 301-316.
14. Blalock, J. E. (1994). The syntax of immune-neuroendocrine communication. Immun. Today, 15, 504-511.
15. Borowski, T., Kokkinidis, L., Merali, Z., & Anisman, H. (1998). Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia. NeuroReport, 9, 3797-3802.
16. Brebner, K., Hayley, S., Merali, Z., & Anisman, H. (2000). Synergistic effects of interleukin-1, interleukin-6, and TNF-α: Neuroendocrine, neurochemical, and behavioral changes. Neuropsychopharmacology, 22, 566-580.
17. Bremner, J. D., Innis, R. B., Salomon, R. M., Staib, L. H., Ng, C. K., Miller, H. L., Bronen, R. A., Krystal, J. H., Duncan, J., Rich, D., Price, L. H., Malison, R., Dey, H., Soufer, R., & Chamey, D. S. (1997). Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch. Gen. Psychiatry, 54, 364-374.
18. Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom. Med., 63, 376-386.
19. Capuron, L., Ravaud, A., & Dantzer, R. (2000). Early depressive symptoms in cancer patients receiving interleukin-2 and/or interferon α-2b therapy. J. Clin. Oncol., 18, 2143-2151.
20. Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F., & Cascinelli, N. (1992). Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur. J. Cancer, 29A, 1266-1269.
21. Connor, T. J., Song, C., Leonard, B. E., Merali, Z., & Anisman, H. (1998). An assesment of the effects of central interleukin-1, -2, -6, and tumor necrosis factor-α administration on some behavioral, neurochemical, endocrine and immune parameters in the rat. Neuroscience, 84, 923-933.
22. Dantzer, R., Bluthe, R. M., Aubert, A., Goodall, G., Bret-Dibat, J.-L., Kent, S., Goujon, E., Laye, S., Parnet, P., & Kelley, K. W. (1999). Mechanisms of the behavioral effects of cytokines. Adv. Exp. Med. Biol., 461, 83-106.
23. Dantzer, R., Bluthe, R. M., Castanon, N., Chauvet, N., Capuron, L., Goodall, G., Kelley, K. W., Konsman, J.-P., Laye, S., Parnet, P., & Pousset, F. (2001). Cytokine effects on behavior. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 703-727). New York: Academic Press.
24. Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson, L., Seipp, L. A., Lotze, M. T., Chang, A. E., Rosenstein, D., & Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med., 107, 293-300.
25. Dunn, A. J. (2001). E3ects of cytokines and infections on brain neurochemistry. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 649-666). New York: Academic Press.
26. Dunn, A. J. (1995). Interactions between the nervous system and the immune system. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 719-731). New York: Raven Press.
27. Ellison, M., Krieg, R. J., & Povlishock, J. T. (1990). Differential central nervous system responses following single and multiple recombinant IL-2 infusions. J. Neuroimmunol., 28, 249-260.
28. Gemma, C., Ghezzi, P., & De Simoni, M. G. (1991). Activation of the hypothalamic serotonergic system by central interleukin-1. Eur. J. Pharmacol., 209, 139-140.
29. Griffiths, J., Ravindran, A. V., Merali, Z., & Anisman, H. (2000). Dysthymia: Neurochemical and behavioral perspectives. Mol. Psychiatry, 5, 242-261.
30. Hanisch, U.-W. (2001). Effects of interleukin-2 and interferons on the nervous system. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 585-631). New York: Academic Press.
31. Hanisch, U.-W., & Quirion, R. (1996). Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev., 21, 246-284.
32. Hanisch, U.-W., Neuhaus, J., Rowe, W., van Rossum, D., Moller, T., Kettenmann, H., & Quirion, R. (1997). Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience, 79, 799-818.
33. Hanisch, U.-W., Rowe, W., Sharma, S., Meaney, M. J., & Quirion, R. (1994). Hypothalamic pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology, 135, 2465-2472.
34. Hanisch, U.-W., Seto, D., & Quirion, R. (1993). Modulation of hippocampal avetylcholine release: A potent central action of interleukin-2. J. Neurosci., 13, 3368-3374.
35. Hayley, S., Lacosta, S., Merali, Z., van Rooijen, N., & Anisman, H. (2001). Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: Sensitization and cross-sensitization effects. Eur. J. Neurosci., 13, 1155-1160.
36. Hayley, S., Brebner, K., Merali, Z., & Anisman, H. (1999). Sensitization to the effects of tumor necrosis factor-α: Neuroendocrine, central monoamine, and behavioral variations. J. Neurosci., 19, 5654-5665.
37. Hebb, A. L. O., Zacharko, R. M., & Anisman, H. (1998). Self-stimulation from the mesencephalon following intraventricular interleukin-2 administration. Brain Res. Bull., 45, 549-556.
38. Herman, J. P., & Cullinan, W. E. (1997). Neurocircuitry of stress: Central control of hypothalamo-pituitary-adrenocortical axis. Trends Neurosci., 20, 78-84.
39. Ho, B. T., Lu, J. G., Huo, Y. Y., Fan, S. H., Meyers, C. A., Tansey, L. W., Payne, R., & Levin, V. A. (1994). Neurochemical basis of interleukin 2-modified discrimination behaviour. Cytokine, 6, 365-367.
40. Ignatowski, T. A., Noble, B. K., Wright, J. R., Gorfien, J. L., Heffner, R. R., & Spengler, R. N. (1997). Neuronal-associated tumor necrosis factor (TNF-α): Its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J. Neuroimmunol., 79, 84-90.
41. Karanth, S., & McCann, S. M. (1991). Anterior pituitary hormone control by interleukin-2. Proc. Natl. Acad. Sri., 88, 2961-2965.
42. Kennedy, S. H., Evans, K. R., Kruger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001). Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry, 158, 899-905.
43. Kronfol, Z., & Remick, D. G. (2000). Cytokines and the brain: Implications for clinical psychiatry. Am. J. Psychiatry, 157, 683-694.
44. Lacosta, S., Merali, Z., & Anisman, H. (2000). Central monoamine alterations associated with acute and repeated interleukin-2 administration. Neuroimmunomodulation, 9, 1-16.
45. Lacosta, S., Merali, Z., & Anisman, H. (1999a). Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav. Neurosci., 113, 1030-1041.
46. Lacosta, S., Merali, Z., & Anisman, H. (1999b). Behavioral and neurochemical consequences of lipopolysaccharide in mice: Anxigenic-like effects. Brain Res., 818, 291-303.
47. Lacosta, S., Merali, Z., & Anisman, H. (1998). Influence of interleukin-1 on exploratory behaviors, plasma ACTH and cortisol, and central biogenic amines in mice. Psychopharmacology, 137, 351-361.
48. Lapchak, P. A. (1992). A role for IL-2 in the regulation of striatal dopaminergic function. Neuro Report, 3, 165-168.
49. Lapchak, P. A., Araujo, D. M., Quirion, R., & Beaudet, A. (1991). Immunoautoradiographic localization of interleukin-2-like immunoreactivity and interleukin-2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neuroscience, 44, 173-184.
50. Licinio, J., & Wong, M. L. (1999). The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry, 4, 317-327.
51. Linthorst, A. C., & Reul, J. M. (1998). Brain neurotransmission during peripheral inflammation. Ann. N. Y. Acad. Set., 840, 139-152.
52. Linthorst, A. C. E., Flachskamm, C., Muller-Preuss, P., Holsboer, F., & Reul, J. M. H. M. (1995). Effect of bacterial endotoxin and interleukin-1b on hippocampal serotonergic neurotransmision, behavioral activity, and free corticosterone levels: An in vivo microdialysis study. J. Neurosci., 15, 2920-2934.
53. Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J., & Rosenberg, S. A. (1985). In vivo administration of purified human interleukin-2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin-2. J. Immunol., 134, 157-166.
54. Lyte, M., Varcoe, J. J., & Bailey, M. T. (1998). Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. Physiol. Behav., 65, 63-68.
55. Maes, M. (1999). Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol., 461, 25-45.
56. Maier, S. F., & Watkins, L. R. (1998). Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev., 105, 83-107.
57. Maier, S. F., Goehler, L. E., Fleshner, M., & Watkins, L. R. (1998). The role of the vagus nerve in cytokine-to-brain communication. Ann. N. Y. Acad. Sci., 840, 289-300.
58. Mann, J. J., Malone, K. M., Diehl, D. J., Perel, J., Nichols, T. E., & Mintun, M. A. (1996). Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J. Cereb. Blood Flow Metab., 16, 418-426.
59. Merali, Z., Lacosta, S., & Anisman, H. (1997). Effects of interleukin-1β and mild stress on alterations of central monoamines: A regional microdialysis study. Brain Res., 761, 225-235.
60. Meyers, C. A. (1999). Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol., 461, 75-81.
61. Meyers, C. A., & Valentine, A. D. (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56-68.
62. Mohankumar, P. S., Thyagarajan, S., & Quadri, S. K. (1993). Interleukin-1β increases 5-hydroxyindoleacetic acid release in the hypothalamus in vivo. Brain Res. Bull., 31, 745-748.
63. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A., Penna, S., Goodkin, R., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001). Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon alpha. New Engl. J. Med., 344, 961-966.
64. Nistico, G., & De Sarro, G. (1991). Is interleukin-2 a neuromodulator in the brain? Trends Neurosci., 14, 146-150.
65. Pauli, S., Linthorst, A. C. E., & Reul, J. M. H. M. (1998). Tumour necrosis factor-α and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat. Eur. J. Neurosci., 10, 178-868.
66. Pettito, J. M., & Huang, Z. (1994). Molecular cloning of a partial cDNA of the interleukin-2 receptor-β in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells. Brain Res., 650, 140-145.
67. Pettito, J. M., & Huang, Z. (1995). Molecular cloning of the coding sequence of an interleukin-2 receptor alpha subunit cDNA in murine brain. J. Neuroimmunol., 59, 135-141.
68. Pettito, J. M., Huang, Z., Raizada, M. K., Rinker, C. M., & McCarthy, D. B. (1997a). Molecular cloning of the coding sequence of an interleukin-2 receptor-gamma (γc) from human and murine forebrain: Expression in the hippocampus in situ and by brain cells in vitro. Brain Res. Mol. Brain Res., 53, 152-162.
69. Petitto, J. M., McCarthy, D. B., Rinker, C. M., Huang, Z., & Getty, T. (1997b). Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol., 73, 183-190.
70. Petitto, J. M., McNamara, R. K., Gendreau, P. L., Huang, Z., & Jackson, A. J. (1999). Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin-2 gene deletion. J. Neurosci. Res., 56, 441-446.
71. Plata-Salaman, C. R. (2000). Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition, 16, 1009-1012.
72. Plata-Salaman, C. R., Sonti, G., Borkoski, J. P., Wilson, C. D., & Ffrench-Mullen, J. M. H. (1996). Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol. Behav., 60, 867-875.
73. Post, R. M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry, 149, 999-1010.
74. Raber, J., & Bloom, F. E. (1994). IL-2 induces vasopressin release from the hypothalamus and the amygdala: Role of nitric oxide-mediated signaling. J. Neurosci., 14, 6187-6195.
75. Raber, J., Koob, G. F., & Bloom, F. E. (1995). Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling: Comparison with the hypothalamic response. J. Pharm. Exp. Ther., 212, 815-824.
76. Rapaport, M. H., & Muller, N. (2001). Immunological states associated with schizophrenia. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 373-382). New York: Academic Press.
77. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmacher, T. (2001). Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry, 58, 445-452.
78. Reichlin, S. (2001). Secretion of neuromodulatory mediators from the brain: An alternative pathway of neuroimmunomodulation. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 499-516). New York: Academic Press.
79. Ritchie, P. K., Ashby, M., Knight, H. H., & Judd, A. M. (1996). Dopamine increases interleukin-6 release and inhibits tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro. Eur. J. Endocrinol., 134, 610-616.
80. Rivier, C. (2001). The hypothalamo-pituitary-adrenal axis response to immune signals. In R. Ader, D. L. Felten, & N. Cohen (Eds.), Psychoneuroimmunology (pp. 633-648). New York: Academic Press.
81. Rothwell, N. J. (1999). Annual review prize lecture cytokines-killers in the brain? J. Physiol., 514, 3-17.
82. Rothwell, N. J., & Luheshi, G. N. (2000). Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci., 12, 618-625.
83. Schmidt, E. D., Janszen, A. W. J. W., Wouterlood, F. G., & Tilders, F. J. H. (1995). Interleukin-1 induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of the ypothalamic-pituitary-adrenal axis. J. Neurosci., 15, 7417-7426.
84. Schmidt, E. D., Binnekade, R., Janszen, A. W., & Tilders, F. J. H. (1996). Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rat. J. Neuroendocrinol., 8, 703-712.
85. Seto, D., Karr, S., & Quirion, R. (1997). Evidence for direct and indirect mechanisms in the potent modulatory action of interleukin-2 on the release of acetylcholine in rat hippocampal slices. Br. J. Pharmacol., 120, 1151-1157.
86. Seto, D., Hanisch, U. K., Villemain, F., Beaudet, A., & Quirion, R. (1993). Anatomical and functional approaches to study of interleukin-2 and its receptors in brain. In E. B. De Souza (Ed.), Methods in neurosciences (vol. 16,. Neurobiology of cytokines, part A pp. 173-184). San Diego: Academic Press.
87. Sluzewska, A. (1999). Indicators of immune activation in depressed patients. Adv. Exp. Med. Biol., 461, 59-74.
88. Song, C., Merali, Z., & Anisman, H. (1999). Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience, 88, 823-836.
89. Sudom, K., Hayley, S., Kelly, O. P., Merali, Z., & Anisman, H. (2001). Influence of chronic cytokine treatments: Neuroendocrine and anhedoniclike effects. Soc. Neurosci. Abst., 27, 634.26.
90. Tilders, F. J. H., & Schmidt, E. D. (1998). Interleukin-1-induced plasticity of hypothalamic CRH neurons and long-term stress hyperresponsiveness. Ann. N. Y. Acad. Sci., 840, 65-73.
91. Tsagarakis, S., Gillies, G., Rees, L. H., Besser, M., & Grossman, A. (1989). Interleukin-1 directly stimulates the release of corticotrophin releasing factor from the rat hypothalamus. Neuroendocrinology, 49, 98-101.
92. Turnbull, A. V., Lee, S., & Rivier, C. (1998). Mechanisms of hypothalamic-pituitary-adrenal axis stimulation by immune signals in the adult rat. Ann. N. Y. Acad. Sci., 840, 434-443.
93. Turnbull, A. V., Pitossi, F. J., Lebrun, J.-J., Lee, S., Meltzer, J. C., Nance, D. M., del Rey, A., Besedovsky, H. O., & Rivier, C. (1997). Inhibition of tumor necrosis factor-a action within the CNS markedely reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats. J. Neuroscience, 17, 3262-3273.
94. Wise, R. A., Bauco, P., Carlezon, W. A., & Trojniar, W. (1992). Self-stimulation and drug reward mechanisms. Ann. N. Y. Acad. Sci., 654, 192-198.
95. Ye, J. H., Tao, L., & Zalcman, S. S. (2001). Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons. Brain Res., 894, 241-248.
96. Yirmiya, R., Pollak, Y., Barak, O., Avitsur, R., Ovadia, H., Bette, M., Weihe, E., & Weidenfeld, J. (2001). Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology, 24, 531-544.
97. Yirimaya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., Barak, O., Reichenberg, A., Cohen, E., Shavit, Y., & Ovadia, H. (1999). Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv. Exp. Med. Biol., 461, 283-316.
98. Zalcman, S. S. (2001). Interleukin-2 potentiates novelty-and GBR 12909-induced exploratory activity. Brain Res., 899, 1-9.
99. Zalcman, S., Green-Johnson, J. M., Murray, L., Nance, D. M., Dyck, D., Anisman, H., & Greenberg, A. (1994). Cytokine-specific central monoamine alterations induced by interleukin (IL)-1, IL-2 and IL-6. Brain Research, 643, 40-49.
100. Zalcman, S., Murray, L., Dyck, D. G., Greenberg, A. M., & Nance, D. M. (1998). Interleukin-2 and -6 induce behavioral-activating effects in mice. Brain Research, 811, 111-121.
101. Zhang, Y.-H., Lu, J., Elmquist, J. K., & Saper, C. B. (2000). Lipopolysaccharide activates specific populations of hypothalamic and brainstem neurons that project to the spinal cord. J. Neuroscience, 20, 6578-6586.